Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 16.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,778 shares of the biotechnology company’s stock after selling 14,747 shares during the period. The Manufacturers Life Insurance Company’s holdings in Sarepta Therapeutics were worth $9,339,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SRPT. Innealta Capital LLC bought a new position in shares of Sarepta Therapeutics during the second quarter worth about $31,000. Nkcfo LLC bought a new position in Sarepta Therapeutics in the 2nd quarter worth approximately $43,000. Huntington National Bank increased its holdings in shares of Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares during the period. Riggs Asset Managment Co. Inc. increased its stake in Sarepta Therapeutics by 33.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 75 shares during the period. Finally, UMB Bank n.a. raised its holdings in Sarepta Therapeutics by 105.9% during the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 197 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on SRPT shares. Raymond James reiterated an “outperform” rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Robert W. Baird lowered their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Citigroup dropped their target price on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their price target for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Sarepta Therapeutics has an average rating of “Moderate Buy” and an average target price of $175.55.

Sarepta Therapeutics Trading Down 1.5 %

Shares of NASDAQ:SRPT opened at $126.01 on Wednesday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The company’s 50-day moving average price is $122.56 and its two-hundred day moving average price is $131.44. The stock has a market capitalization of $12.04 billion, a PE ratio of 100.81 and a beta of 0.77. Sarepta Therapeutics, Inc. has a one year low of $83.97 and a one year high of $173.25.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.